Vitiligo

Spatial transcriptomics reveals how UVB phototherapy calms vitiligo skin, silencing IFN-γ pathways and memory T cells to drive repigmentation.

A new systematic review shows vitiligo’s stigma-driven mental health and quality-of-life burden varies by culture, urging culturally tailored, multidisciplinary care and education.

Oral therapies may provide more widespread and effective repigmentation, especially in extensive nonsegmental vitiligo.

A retrospective claims analysis found that nearly half of patients newly diagnosed with vitiligo by a dermatologist did not initiate therapy, and those who did showed low persistence across treatment categories.

Late-breaking data presented at AAD 2026 showed that upadacitinib 15 mg produced statistically significant, progressively improving repigmentation in adults and adolescents with non-segmental vitiligo through 48 weeks.

This review of the latest dermatological studies includes insights on vitiligo cultural beliefs, home-based phototherapy, digital search behavior in NSV patients, and more.

Misconceptions about vitiligo, including contagion and supernatural causation, remain prevalent in many regions and are linked to increased stigma.

In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use.

Susan C. Taylor, MD, moderated a recent Case-Based Roundtable discussion on topical treatment options for vitiligo.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Real-world data from Saudi Arabia show vitiligo combination therapy with narrowband UVB or Janus kinase inhibitors drives steeper VASI improvement than monotherapy.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

This review of the latest vitiligo studies includes insights on the efficacy of ritlecitinib, the risk of herpes zoster, oxidative stress in red blood cells for this patient population, and more.

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Christopher Bunick, MD, PhD, led a vital discussion on innovative vitiligo treatments, emphasizing combination therapies and psychosocial support for effective management.

As 2025 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Erik Domingues leads a vital discussion on innovative vitiligo management, addressing treatment challenges and psychosocial impacts in diverse patient populations.

Experts discuss innovative strategies for vitiligo treatment, emphasizing the role of topical Janus kinase inhibitors and effective patient communication for optimal outcomes.

Discover how anatomical variations impact the minimal erythema dose in 308-nm excimer laser therapy for vitiligo in Asian patients.

A nationwide survey in Japan reveals significant health-related quality of life and psychological challenges faced by patients with vitiligo, highlighting the need for better mental health support.

AI could revolutionize vitiligo management with enhanced diagnostics, automated tracking, and personalized treatment forecasting, improving patient care and outcomes.

The study supports the hypothesis that targeting oxidative stress could complement phototherapy in restoring pigmentation in vitiligo.

Marc Serota, MD, notes that areas lacking hair follicles respond more slowly to therapy and benefit from long-term, low-risk use of topical ruxolitinib.

Lindsay Ackerman, MD, FAAD, shares practical insights on managing vitiligo with topical ruxolitinib, addressing patient expectations, safety, and evolving research gaps.

In 2 replicate phase 3 trials, once-daily upadacitinib 15 mg significantly improved total and facial repigmentation in adults and adolescents with non-segmental vitiligo, with a safety profile consistent with prior indications.